ARTICLE OPEN Check for updates Incidental findings from cancer next generation sequencing panels

Nika Maani^{1,2}, Karen Panabaker³, Jeanna M. McCuaig^{2,4}, Kathleen Buckley⁵, Kara Semotiuk⁶, Kirsten M. Farncombe⁷, Peter Ainsworth⁸, Seema Panchal^{2,9}, Bekim Sadikovic^{8,10}, Susan Randall Armel^{2,4}, Hanxin Lin^{8,10,12¹} and Raymond H. Kim^{4,11,12¹}

Next-generation sequencing (NGS) technologies have facilitated multi-gene panel (MGP) testing to detect germline DNA variants in hereditary cancer patients. This sensitive technique can uncover unexpected, non-germline incidental findings indicative of mosaicism, clonal hematopoiesis (CH), or hematologic malignancies. A retrospective chart review was conducted to identify cases of incidental findings from NGS-MGP testing. Inclusion criteria included: 1) multiple pathogenic variants in the same patient; 2) pathogenic variants at a low allele fraction; and/or 3) the presence of pathogenic variants not consistent with family history. Secondary tissue analysis, complete blood count (CBC) and medical record review were conducted to further delineate the etiology of the pathogenic variants. Of 6060 NGS-MGP tests, 24 cases fulfilling our inclusion criteria were identified. Pathogenic variants were detected in *TP53, ATM, CHEK2, BRCA1* and *APC*. 18/24 (75.0%) patients were classified as CH, 3/24 (12.5%) as mosaic, 2/24 (8.3%) related to a hematologic malignancy, and 1/24 (4.2%) as true germline. We describe a case-specific workflow to identify and interpret the nature of incidental findings on NGS-MGP. This workflow will provide oncology and genetic clinics a practical guide for the management and counselling of patients with unexpected NGS-MGP findings.

npj Genomic Medicine (2021)6:63; https://doi.org/10.1038/s41525-021-00224-6

INTRODUCTION

Blood-based genetic testing is a mainstay in the approach of hereditary cancer assessment¹⁻⁷. Such genetic testing typically involves the analysis of DNA isolated from peripheral blood leukocytes (PBLs)^{3,8,9}, with the assumption that leukocyte DNA is representative of the germline⁸⁻¹⁰. Most hereditary cancer syndromes are inherited in a monoallelic fashion with an expected 50% allele fraction (AF)⁸. Compared to traditional Sanger sequencing, next generation sequencing (NGS) technologies and the development of multi-gene panel (MGP) testing have significantly improved assay sensitivity and enabled the ability to test multiple genes simultaneously^{4,8,9,11}. In a minority of cases, atypical genetic test results can be observed following NGS-MGP testing, which are not consistent with a monoallelic germline variant. Examples include the detection of variants with low AFs (<30%)^{3,8,9,12}, multiple pathogenic variants in the same individual, and genetic testing results which are not congruent with the reported family history^{13,14}. When derived from the analysis of PBLs, these unexpected genetic results may indicate a *de novo* germline event¹⁵, or a genetic variant of non-germline origin. These results could be considered incidental findings¹⁶, as they are outside of the original purpose for which the test or procedure was conducted¹⁷. Non-germline findings include post-zygotic mosaicism, hematologic malignancy, or clonal hematopoesis (CH) (a newly recognized phenomenon where genetic changes accumulate in myeloid cells)^{3,5,6,8}.

CH is a recently described phenomenon in which somatic variants accumulate in PBL due to aging and exposure to therapies such as chemotherapy and radiotherapy^{8,18–20}. These somatic variants can

lead to precursors for neoplasms of undetermined significance^{18,21-23}. Clinically, a growing body of evidence has uncovered a link between CH and a two to four-fold increased risk of atherosclerotic disease^{18,24–28}, along with an increased risk for the development of overt hematologic neoplasia and increased overall mortality in CH patients²⁹. Mosaicism is typically defined as the presence of genetically distinct populations of cells within an individual, following acquired change(s) occurring shortly after zygote formation^{30,31}. If these changes are present in the gametes and involve germline cells, they may be transmissible to offspring^{9,10,30-32}. Postnatally, further somatic tissue-specific genetic changes can be acquired and can lead to the development of cancer⁸⁻¹⁰. When somatic variants are detected exclusively in PBLs, they can be indicative of a hematological malignancy or CH^{8,9,33} and may lead to clonal expansion in the blood^{21,34}. PBL-isolated variants, however, are not transmissible to offspring and their identification is important as patients carrying such variants are managed differently from those harbouring germline variants.

Given the increased uptake of NGS-MGP testing, there exists a growing need for the development of a workflow to both identify and manage the clinical follow-up of patients who present with potentially non-germline incidental findings. To further explore the management of patients presenting with potential incidental findings following germline NGS-MGP testing, we performed a retrospective chart review of individuals who underwent hereditary cancer NGS-MGP testing in Ontario with findings suspicious of a non-germline incidental finding and propose a clinical workup.



¹Program for Genetics and Genome Biology, Hospital for Sick Children, Toronto, ON, Canada. ²Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. ³Medical Genetics Program of Southwestern Ontario, London Health Sciences Centre, London, ON, Canada. ⁴Familial Cancer Clinic, Princess Margaret Hospital Cancer Centre, Toronto, ON, Canada. ⁵Grand River Hospital, Kitchener, ON, Canada. ⁶Zane Cohen Centre for Digestive Diseases, Familial Gastrointestinal Cancer Registry, Mount Sinai Hospital, Toronto, ON, Canada. ⁷Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada. ⁸Molecular Genetics Laboratory, Division of Molecular Diagnostics, London Health Sciences Centre, London, ON, Canada. ⁹Familial Breast Cancer Clinic, Mount Sinai Hospital, Toronto, ON, Canada. ¹⁰Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada. ¹¹Department of Medicine, University of Toronto, ON, Canada. ¹²These authors contributed equally: Hanxin Lin, Raymond H. Kim. ⁵²email: hanxinlin@lhsc.on.ca; raymond.kim@uhn.ca

RESULTS

Patient population

Between January 1, 2016 and December 31, 2019, 6060 patients with a personal or strong family history of cancer who were referred to a hereditary cancer clinic in Ontario on suspicion of a hereditary cancer syndrome consented to have NGS-MGP testing. All 6060 patients underwent a germline comprehensive hereditary cancer NGS panel at the Molecular Genetics Laboratory at London Health Sciences Centre in Ontario, Canada. Of these 6060 patients, 24 (0.4%) fulfilled the inclusion criteria suggestive of an incidental finding (Table 1). For patients with unquantified low allele fractions from an external laboratory (Patients 2, 33, 40), NGS-MGP was repeated at London Health Sciences Centre. To better understand the origin of these variants, NGS-MGP was conducted on secondary tissues and blood collected at different time points. This secondary testing was done in conjunction with a review of the patient's medical history (including complete blood counts [CBCs]) to monitor for the presence or potential development of a hematologic disorder.

Genetic testing results

Twenty-four patients fulfilled the inclusion criteria and underwent further investigation of secondary tissues and an assessment for CH and leukemia (Table 2). Four out of twenty-four (16.6%) patients had multiple pathogenic variants (Category 1), 18/24 (75%) patients had low AFs (Category 2), and 17/24 (70%) patients whose family histories were not suggestive of Li-Fraumeni syndrome (non-Chompret) had TP53 variants (Category 3). Of note, many patients fit into more than one category. Identified cases involved 5 different hereditary cancer genes; the most common being TP53. Of the 24 patients in our cohort, 17 (70%) had findings in TP53, 2 (8.3%) in CHEK2, 3 (12.5%) in ATM, 2 (8.3%) in APC and 2 (8.3%) in BRCA1. Two out of twenty-four (8.3%) patients had pathogenic variants in more than one gene. To understand the origin of these variants, peripheral blood was collected at different time points when possible, and multiple AFs were obtained. Heterozygous variants were expected to have an AF of approximately 50%; however, in the case of non-germline variants, the AF may significantly fluctuate.

Secondary tissue analysis

Fibroblast culturing has been reported to boost allelic fractions of variants that confer a growth advantage, suggesting that fibroblasts harbouring pathogenic variants in tumour suppressor genes may be present in cultured samples³⁵. To further delineate this in our cohort, patients underwent a skin biopsy (direct and/or cultured). Eleven out of twenty-four (45.8%) patients underwent NGS-MGP analysis of a direct skin punch biopsy. Of these, 7 (63.6%) had a paired cultured skin biopsy. Four out of eleven (36.3%) patients (11, 12, 13, and 18) harboured low levels of PBL variants in direct skin biopsy samples and upon fibroblast culturing, these variants were no longer observed (Table 2). This suggests PBL contamination of the direct skin punch biopsies and is suggestive of CH. This was also observed in Patient 10, in which an additional second and third pathogenic variant in TP53 were identified in direct skin punch biopsy. These variants were different than those initially identified in PBL-derived DNA and in cultured fibroblasts (Table 2), suggesting the presence of sequencing artifacts or somatic events occurring in the skin. Sample mix-up was ruled out by the assessment of three unique SNPs on skin and blood samples and results were confirmed using an additional NGS chemistry and sequencer. Taken together, the two additional variants found in the direct skin biopsy were likely somatic events isolated to the skin which have been observed in healthy individuals³⁶⁻³⁸. Conversely, Patient 6 harboured low levels of a TP53 variant in direct skin punch biopsy, suggestive of PBL contamination in the biopsy sample. A cultured fibroblast sample for this patient was not available and it was ultimately concluded that this patient likely had CH (Table 2).

Three out of twenty-four (12.5%) patients underwent tumour tissue analysis. Patient 40 was mosaic for *APC*; patient 41 had a *TP53* variant present in the tumour at a low level, but did not have the second *APC* variant (Table 2). This case was considered likely due to CH and the tumour results due to the presence of admixed leukocytes of CH origin in tumour tissues. This phenomenon has also been reported in other tumour sequencing studies^{5,22}. Lastly, skin and tumour samples in Patient 3 were negative for the *TP53* variant detected in PBL, suggesting CH.

Diagnostic algorithm and conclusions

Diagnostic conclusions for patients in our cohort were made using a specific algorithm (Fig. 1). Patients were considered to have a confirmed full germline hereditary cancer syndrome if the variant was found at >30% AF in PBL and cultured fibroblasts [1/24 (4.2%)]. Patients were classified as mosaic if the variant was detected at a < 30% AF in PBL-derived DNA and was also detected in a second tissue [3/24 (12.5%)]. Mosaic patients were clinically managed using relevant hereditary cancer syndrome screening guidelines.

Nine out of twenty-four (37.5%) patients had a variant with an AF (< 30%) in PBL, which was either absent, or present in low levels in secondary tissues (results from cultured fibroblasts were used if there was a discrepancy with direct skin biopsy results). These patients were further evaluated for CH or a hematologic malignancy through a thorough review of CBC and medical charts (Fig. 1). If the CBC was normal and there was no evidence of hematologic malignancy upon medical chart review, patients were classified as CH [8/24 (33.3%)] (Fig. 1, Table 2). Molecular findings such as low AFs, normal CBC and exposure to chemotherapy were considered to support a diagnosis of CH. Fluctuating AF was also supportive of CH, however, this finding alone may be insufficient evidence of CH as the variance between timepoints was not assessed. Higher AFs and positive family history were considered suggestive of an inherited syndrome. Under this criteria, an additional 10 patients were classified as "likely CH" based on clinical history despite not having secondary tissue analysis. Combining these 10 patients with the 8 CH cases confirmed through secondary tissue analysis, 18/24 (75.0%) patients were concluded to have CH, representing a majority of our cohort. Of interest, 14/18 CH patients (77.7%) had a history of chemotherapy (Tables 1 and 2). In keeping with the ever-evolving clinical impact of CH, patients with findings suggestive of CH were enrolled into a research program assessing cardiovascular risk reduction^{18,24}

Lastly, 2 out of 24 (8.3%) patients were diagnosed with a hematologic malignancy. Patient 11 had an elevated white blood cell count and was diagnosed with chronic lymphoblastic leukemia whilst simultaneously undergoing germline testing. Patient 12 did not disclose their multiple myeloma diagnosis during the initial genetics consultation. Upon further review of their medical chart, it was noted they had been lost to follow-up regarding this diagnosis and was subsequently re-referred to their hematologist for ongoing care. These cases highlight the importance of a thorough medical history review for all patients undergoing a genetics assessment.

DISCUSSION

This retrospective chart review investigated incidental findings identified through NGS-MGP testing for hereditary cancer syndrome identification. These findings were considered incidental as they were unexpected from the original reason for NGS-MGP¹⁷. Genetic findings meriting further investigation for an incidental finding include: (1) multiple pathogenic variants in the same individual, (2) low AFs, and (3) pathogenic variants not consistent with personal and/or family cancer history (e.g. non-Chompret^{8,39})

Public line in the interval of the int								
2 1	Patient ID	Sex	Ethnicity	Cancer	Age at Cancer Diagnosis	History of Systemic Chemotherapy (Y/N)	WBC (10 ⁹)	Family Cancer Hx
I Image: mail Bioard Bioard<	2	u	Ashkenazi Jewish	Breast	52	×	6.8	FDR: 3 (Melanoma + Prostate: Basal Cell Carcinoma: Breast +
3 1	I			Breast	63		}	Melanoma); SDR: 7 (Kidney; Prostate; Breast; Breast; Colon + Melanoma: Ovary: Breast)
6 1 0 NM NM 7 F InpluS Secon Onlini N N 7 F InpluS Decid Cactorian bCui N N 8 F Cuatation Decid Cactorian bCui N N N 8 F Cuatation Decid Cactorian bCui 2 N N N 8 Cuatation Decid Cactorian bCui 2 N N N N 1 F Cuatation Decid Cactorian bCui 2 N	ŝ	ш	English	Serous Ovarian	78	Y	4.9	FDR: 1 (Cervical)
6 1 1 0	5	ш	English/Scottish/ German	Serous Ovarian	68	NA	NA	NA
	9	ш	British	None	NA	z	7.5	FDR: 1 (Ovarian); SDR: 1 (Breast)
8 1 Induct Englation 1 2 SPA 4 Sucrems Lung Produce Genet Provid Genet 2	7	щ	Caucasian	Ductal Carcinoma In-Situ	37	z	6.2	SDR: 13 (Breast; Lung; Lung; Breast; Breast; Breast; Breast; Lung + Liver; Pancreas; Pancreas; Pancreas; Brain)
Thrund Carter and Bases Constraine and Second Continue and Second C	8	ш	lrish/ English	Hodgkin's Lymphoma	21 and 29	٨	7.5	SDR: 4 (Sarcoma; Lung; Prostate; Breast)
International series Internat				Thyroid Cancer	40			
17Secus Orania701FSeptiatic LooidhSecus Orania7012FDR 7 (freductine Produte + Thyroid)1FEuropean Ahloward JewichPeartSecus Orania7072FDR 7 (freductine Produte + Thyroid)1FEuropean Ahloward JewichPeartPeartPeartPeartPeart12FCuerasianEuropean Ahloward JewichPeartPeartPeartPeart13FKentonicEuropean Ahloward JewichPeartPeartPeartPeart14FSecus Oranian22YNNNPeartPeart15FMethodieSecus Oranian23YNNNNN16FLundianControl23YNNNNNN17Lundian French,Secus Oranian23YNNNNNNN18FLundian FrenchControlNNN				Breast	65			
10 F Spendic Jondin Scots Ondin 54 Y 123 FOST Clicktour: Ponchanis. Result 11 F European Ankhenzal Jendin Board Scots Ordinan Board 12 F European Ankhenzal Jendin Board F Scots Ordinan Board 13 F Cucasian BO F F Scots Ordinan				Serous Ovarian	70			
11 E Lungen, Athlemed Jeoki, Instructione (Decisione) Break). Dest Total Carcinone Break). 12 Cunctione Dest 2 N PDE<4 (Science) Free Reaken.	10	ш	Sephardic Jewish	Serous Ovarian	54	×	12.2	FDR: 2 (Testicular; Prostate + Thyroid)
1 Clonck (wynboltsik: 22 Y SR 4 (F3), Breast Leukenia: Hodjón's (yrphona) 12 F Cucusian Ok Kopa Myelona 2 Y S6 FD8 3 (preast Leukenia: Contron-regional SDF 5 faukenia: Contron-regranteregrand SDF 5 faukenia: Contron-regranteregrant	11	ш	European, Ashkenazi Jewish	Breast	59	×	84.9	FDR: 4 (Basal Cell Carcinoma; Bone; Basal Cell Carcinoma; Breast);
12 F Concrision Op/ Rays Myclona 22 Y Science (Contrinction) Sci				Chronic Lymphoblastic Leukemia	72			SDR: 4 (PSU; Breast; Leukemia; Hodgkin's Lymphoma)
1 Colon 39 Number of Maderonal Breast Breast 1 F Sit Lanham Secosi Oonian 86 PCR Reset: Breast Breast Secosi Oonian 1 F Sit Lanham Secosi Oonian 80 N NA FOR 1 (Breast-Lung): SOR 4 (Brant: Breast: Breast; Stonad) 16 F Interh Secosi Oonian 80 N No No 16 F Interh Secosi Oonian 20 N No No 16 F Interh Secosi Oonian 20 N No No 17 F Breath Secosi Oonian 20 N No 100	12	ш	Caucasian	lgA Kappa Myeloma	72	~	5.6	FDR: 3 (Polyps; Polyps; Gastrointestinal) SDR: 5 (Leukemia;
13 F West Indies Beast Oration Serves				Colon	79			Lymphoma; Melanoma; Breast: Breast)
14 F Si Lahdan Serois Oorian 00 No. 15 F Extindian Serois Oorian 0 NA No. 16 F Extindian Oronian 20 NA No. 16 F Extindian Oronian 20 No. Serois Oracian 20 16 F Extindian Oronian 62 N Ano. Serois Oracian 20 17 E Brith/French. Colorectal Adenomas 62 N 72 EPR. 1 (Oronin); SPR.1 (Colon) 24 F F Frongh/Mich Beast 24 2 2 24 F F Frongh/Mich Beast 26 2 2 2 2 24 F F Frongh/Mich Beast 26 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	13	ш	West Indies	Breast	51	~	5.8	FDR: 1 (Breast + Lung); SDR: 5 (Breast; Ovarian; Lung; Lung; Ovarian)
15 F Dutch Serous Oranian 70 NA None 16 F Extinution Carous Oranian 78 Y 49 SDF. 1 (corrical) SDF. 1 (corrical) 18 F Larvian, French, serous Oranian 78 Y 49 SDF. 1 (corrical) SDF. 1 (corrical) 19 F Ritish/French Correctal Adenomas 52 Y 72 FDR. 1 (conon) 20 F Sorous Uterne 70 Y 72 FDR. 1 (conon) 21 F Sorous Uterne 26 Y 72 FDR. 1 (conon) 21 F Sorous Uterne 26 Y 26 Constanty Colony Brain) 22 F F Sorous Uterne 26 Y 26 FDR. 2 (Breact, Breast, Bre	14	ш	Sri Lankan	Serous Ovarian	80	~	AN	FDR: 1 (Stomach); SDR: 4 (Brain; Breast; Breast; Stomach)
16 F East Indian Oratian 60 Y 39 D.R.I. (Carcia) 17 F Lavian, French, French, French, Gorectal Adenomas 22 N 105 FDR. I. (Colon) 19 F British/French Gorectal Adenomas 22 N 105 FDR. I. (Colon) 10 F British/French Gorectal Adenomas 22 Y 23 FDR. I. (Colon) 24 F Slownian Breast 98 7 23 FDR. I. (Colon) 24 F British/French Gorectal Adenomas 23 Y 23 FDR. I. (Colon) 24 F Foronian 54 Y 26 FDR. I. (Colon) 26 N F FOR I. (Colon) 26 FDR. I. (Colon) 27 E F FOR I. (Colon) 7 FDR. I. (Colon) 26 N FDR. I. (Colon) 7 FDR. I. (Colon) 7 27 FDR. I. (Colon) FDR. I. (Colon) 7	15	ш	Dutch	Serous Ovarian	70	NA	NA	None
18 I alvionity Serous Ovarian 78 Y 8.1 CDM II Chancell Cell Bladder) 19 F Britih/French, Colorectal Aderomas 62 N 72 FDR II (Colon) 22 F Slovenian 62 N 72 FDR II (Colon) 24 F English/frich Breast 63 Y 23 24 F English/frich Breast 63 Y 80 FDR II (Performeal); SDR 7 (Breast, Breast; Innon; Din On on in Breast <	16	ш	East Indian	Ovarian	60	Y	4.9	SDR: 1 (Cervical)
10 F British/Frech Colorectal Adenomas 62 N 105 FDR: 1 (Ovarian): SDR: 1 (Colon) 24 F Sovenian Polycythemia Vera 32 Y 72 FDR: 1 (Porarian): SDR: 7 (Breast, Breast,	18	ш	Latvian, French, Ashkenazi Jewish	Serous Ovarian	78	٨	8.1	FDR: 1 (Small Cell); SDR: 2 (Bladder; Small Cell Bladder)
21 F Sovenian 20 7 72 F0 1; (clon) 24 F English/rich Beast 3 Y A 24 Devenian 5 A A A A 24 Devenish 5 A A A A 24 Devenish Breast 6 A A A 24 Devenish Breast 6 A A A 24 E English/fich Breast 6 A A 27 F English/fich Breast 6 A A 26 M A A A A A 28 Enst Breast A A A A 26 Constance Secus Constan Secus Constan A A A 28 French Canadian Breast Breast A A A A A <td< td=""><td>19</td><td>ш</td><td>British/French</td><td>Colorectal Adenomas</td><td>62</td><td>z</td><td>10.6</td><td>FDR: 1 (Ovarian); SDR:1 (Colon)</td></td<>	19	ш	British/French	Colorectal Adenomas	62	z	10.6	FDR: 1 (Ovarian); SDR:1 (Colon)
24 F Fendlish/Insh Serous Uterine 70 24 7 0xarian 38 Y 80 PDR. I Perifoneal); SDR. 7 (Breast, Breast, Doario) 24	22	ш	Slovenian	Polycythemia Vera	52	×	7.2	FDR 1: (Colon)
24 F English/rich Breast 38 Y 0varian; SDR: 7 (Breast, Breast, B				Serous Uterine	70			
	24	ш	English/Irish	Breast	38	~	8.0	FDR: 1 (Peritoneal); SDR: 7 (Breast, Breast; Breast; Breast; Breast+
1 Breast 63 27 Lung 71 28 Lung 71 1 Breast 63 29 M Eastern European 10 Breast 56 1 28 29 M Eastern European Prostate 29 M Eastern European Prostate 33 F French Canadian Prostate 34 F French Canadian Breast 35 N 41 41 F0R: 1 (Breast) Europain; Eudemia: Eudemia + Prostate 36 N 23 Y 41 F0 40 F Caucasian 56 N 53 41 F Caucasian 50 N 53 42 M Caucasian 53 Y 56 43 F Scottish/Mish Breast (male) 50 50 50 50 50 50 50 50 50				Ovarian	54			Ovarian; Colon; Brain)
27 F English/Scottish Lung 71 27 F English/Scottish Breast 48 γ 6.8 FDR. 2 (Breast, Gastric); SDR. 2 (Brain; Breast) 29 M Eastern European Postate 53 γ 10.4 FDR. 2 (Breast, Gastric); SDR. 3 (Leukemia, Leukemia + Prostate) 33 F French Canadian Breast 35 γ 4.1 FDR. 1 (Bladder); SDR. 6 (Bone; Lung; Lung + Liver; Skin; Breast, Lung) 33 F French Canadian Breast 35 γ 4.1 FDR. 1 (Bladder); SDR. 6 (Bone; Lung; Lung + Liver; Skin; Breast, Lung) 34 F Cucasian 56 N 5.3 FDR. 1 (Breast) 40 F Cucasian 58 N 7.3 FDR. 5 (Breast; Breast; Unknown; Unknown; 41 F Cucasian 58 N 7 7.3 FDR. 5 (Skin; Skin; Breast; Unknown; Unknown; 42 M Cucasian FS FDR. 1 (Breast) FDR. 5 (Skin; Skin; Preast; Breast; Unknown; Unknown; 42 M Cucasian FS FDR. 1 (Breast) FDR. 1 (Breast) FDR. 1 (Breast) <td></td> <td></td> <td></td> <td>Breast</td> <td>63</td> <td></td> <td></td> <td></td>				Breast	63			
27 F English/Scottish Breast 68 Y 6.8 FDR: 2 (Breast, Gastric); SDR: 2 (Brain, Breast) 29 M Easten European Prostate 53 Y 10.4 FDR: 2 (Breast, Gastric); SDR: 3 (Leukemia, Leukemia + Prostate) 33 F French Canadian Breast 33 Y 4.1 FDR: 1 (Bladder); SDR: 6 (Bone; Lung; Lung + Liver; Skin; Breast; Lung) 34 F Caucasian 56 Y 4.1 FDR: 1 (Bladder); SDR: 6 (Bone; Lung; Lung + Liver; Skin; Breast; Lung) 40 F Caucasian 56 Y 4.1 FDR: 1 (Bladder); SDR: 6 (Bone; Lung; Lung + Liver; Skin; Breast; Lung) 41 F Caucasian 56 Y 4.1 FDR: 1 (Breast) 42 F Caucasian 53 FDR: 1 (Breast) FDR: 1 (Breast) 43 F Scottish/Irish Breast (male) 72 Y 44 Actorish/Irish Breast 10, PR 56 FDR: 1 (Breast) 45 K Coutish/Irish Breast (male) 77 73 46 F 70 7 73 FDR: 1 (Breast) 47 Actish/Irish Breast (male) 72 Y 48 Scottish/Irish <td></td> <td></td> <td></td> <td>Lung</td> <td>71</td> <td></td> <td></td> <td></td>				Lung	71			
29MBreast5629MEasten EuropeanBreast6733FFrench CanadianProstate53Y34FFrench CanadianBreast35Y33FFFrench CanadianBreast4.1FDR: 2 (Breast, Melanoma); SDR: 3 (Leukemia; Leukemia + Prostate; Breast)34FFrench CanadianBreast35Y4.1FDR: 1 (Bladder); SDR: 6 (Bone; Lung; Lung; Lung; Lung; Lung; Lung; Lung; Lung); SDR: 5 (Breast; Breast; Unknown; Unknown; Unknown)40FCaucasian2.9N7.3FDR: 2 (Lung; Lung); SDR: 5 (Breast; Breast; Unknown; Unknown; Unknown)41FScottish/IrishBreast72Y7.3Unknown)42MCaucasian55Y5.6FDR: 1 (Skin); SDR: 5 (Skin; Skin; Pancreas; Brain; Brain)43FScottish/IrishBreast5Y7.3Unknown)44FScottish/IrishBreast7.2Y5.6FDR: 1 (Thyroid; Pancreas; Brain; Brain)45FScottish/IrishBreast7.3Y10.7FDR: 2 (Invoid; Pancreas; Brain; Brain)46FScottish/IrishBreast7.2Y7.3Unknown)47FScottish/IrishBreast7.3Y7.3Y/Y St/No/N48FScottish/IrishBreast7.3Y10.7FDR: 2 (Invoid; Pancreas; Breast; Breast; Horavin)48FScottish/Iris	27	ш	English/Scottish	Breast	48	~	6.8	FDR: 2 (Breast; Gastric); SDR: 2 (Brain; Breast)
29 M Breast Clause 53 Y 10.4 FDR: 2 (Breast, Melanoma); SDR: 3 (Leukemia; Leukemia + Prostate; Breast) 33 F French Canadian Breast) 8. 4.1 FDR: 2 (Breast, Melanoma); SDR: 3 (Leukemia; Leukemia + Prostate; Breast; Lung) 33 F French Canadian Breast 4.1 FDR: 1 (Bladder); SDR: 6 (Bone; Lung; Lung + Liver; Skin; Breast; Lung) 40 F Ovarian 56 N 7.3 FDR: 1 (Bladder); SDR: 6 (Bone; Lung; Lung + Liver; Skin; Breast; Lung) 41 F Caucasian 5.3 FDR: 1 (Bladder); SDR: 6 (Bone; Lung; Lung + Liver; Skin; Breast; Lung) 42 M Caucasian 5.3 FDR: 1 (Breast) 7.3 EDR: 2 (Lung; Lung); SDR: 5 (Breast; Breast; Unknown; Unknown; 43 F Scottish/Nish Breast 7.3 FDR: 2 (Lung; Lung); SDR: 5 (Skin; Skin; Pancreas; Breast; Unknown; 43 F Scottish/Nish Breast 7.3 Y 5.6 FDR: 1 (Skin); SDR: 5 (Skin; Skin; Pancreas; Breast; Unknown; 44 F Scottish/Nish Breast 7.3 Y 7.3 Unknown) 45 F Scottish/Nish <td< td=""><td></td><td></td><td></td><td>Breast</td><td>56</td><td></td><td></td><td></td></td<>				Breast	56			
29 M Eastern European Prostate 53 Y 10,4 FDR: 2 (Breast, Melanoma); SDR: 3 (Leukemia; Leukemia + Prostate; Breast) 33 F French Canadian Breast 35 Y 4.1 FDR: 1 (Bladder); SDR: 6 (Bone; Lung; Lung + Liver; Skin; Breast, Lung) 33 F Rench Canadian Breast 35 Y 4.1 FDR: 1 (Bladder); SDR: 6 (Bone; Lung; Lung + Liver; Skin; Breast, Lung) 40 F Ovarian 58 N 5.3 FDR: 1 (Breast) 41 F Scotish Breast 7.3 FDR: 1 (Breast) 42 M Caucasian Breast (male) 7.3 PDR: 1 (Breast) 43 F Scotish Breast (male) 7.3 PDR: 1 (Skin); SDR: 5 (Skin; Skin; Pancreas; Brain) 43 F Scotish/Irish Breast (male) 7.3 Y 7.3 PDR: 1 (Skin); SDR: 5 (Skin; Sin; Pancreas; Brain) 43 F Scotish/Irish Breast (male) 7.3 Y 7.3 PDR: 2 (Thyroid; Pancreas; Brain) 43 F Scotish/Irish Breast (male) 7.3 Y 7.3 PDR: 2 (Skin; Skin; Pancreas; Brain) 43 F Scotish/Irish Breast (male) 5.5 Y 7.3 PDR				Breast	67			
33 F French Canadian Breast 35 Y 4.1 FDR: 1 (Bladder); 5DR: 6 (Bone; Lung: Lung + Liver; Skin; Breast; Lung) 40 F Ovarian 58 N 5.3 FDR: 1 (Breast) 40 F Cucasian 58 N 5.3 FDR: 1 (Breast) 41 F Scottish Breast 70 Y 7.3 FDR: 2 (Lung; Lung); SDR: 5 (Breast; Breast; Unknown; Unknown) 42 M Caucasian 72 Y 7.3 FDR: 2 (Lung; Lung); SDR: 5 (Breast; Breast; Unknown; Unknown) 43 F Scottish/Irish Breast (male) 72 Y 5.6 FDR: 1 (Skin); SDR: 5 (Skin; Skin; Pancreas; Brain; Brain) 43 F Scottish/Irish Breast (male) 72 Y 10.7 FDR: 2 (Thyroid; Pancreas); SDR: 2 (Breast; Breast; Hoart) 44 NBC NH count, AK History <i>FDR</i> First Degree Relative, SDR Second Decree Relative, V/N Yes/No, AM ot available. 10.7 FDR: 2 (Thyroid; Pancreas); SDR: 2 (Breast; Breast; Hoart)	29	٤	Eastern European	Prostate	53	Y	10.4	FDR: 2 (Breast; Melanoma); SDR: 3 (Leukemia; Leukemia + Prostate; Breast)
40 F Carcasian 56 40 F Carcasian 58 41 F Scottish Breast 70 Y 7.3 FDR: 1 (Breast) 42 M Carcasian 87 7 7.3 FDR: 2 (Lung): SDR: 5 (Breast; Breast; Unknown; Unknown) 43 F Scottish/Irish Breast 7 Y 5.6 FDR: 1 (Skin); SDR: 5 (Skin; Skin; Pancreas; Brain; Brain) 43 F Scottish/Irish Breast 9.0 10.7 FDR: 2 (Thyroid; Pancreas); SDR: 2 (Breast; Breast; Hovary) MC White Blood Cell Count, <i>IAk</i> History <i>FDR</i> First Degree Relative. <i>SDR</i> Second Decree Relative, <i>NN</i> Yes/No. M Not available. 10.7 FDR: 2 (Thyroid; Pancreas); SDR: 2 (Breast; Breast; Hovary)	33	ш	French Canadian	Breast	35	٨	4.1	FDR: 1 (Bladder); SDR: 6 (Bone; Lung; Lung + Liver; Skin; Breast; Lung)
Ovarian Search				Serous Ovarian	56			
40 F Caucasian >100 Adenomas 29 N 5.3 FDR: 1 (Breast) 41 F Scottish Breast 7 Y 7.3 FDR: 2 (Lung); SDR: 5 (Breast; Breast; Unknown; Unknown; 41 F Scottish Breast 7 Y 7.3 FDR: 2 (Lung); SDR: 5 (Breast; Breast; Unknown; Unknown; 42 M Caucasian Breast (male) 72 Y 5.6 FDR: 1 (Skin); SDR: 5 (Skin; Skin; Pancreas; Brain; Brain) 43 F Scottish/Irish Breast 55 Y 10.7 FDR: 2 (Thyroid; Pancreas); SDR: 2 (Breast; Breast + Ovary) MSC White Blood Cell Count. <i>Hx</i> History <i>FDR</i> First Degree Relative. <i>SDR</i> Second Degree Relative, <i>NN</i> Yes/No. MA not available. Mod available.				Ovarian	58			
41 F Scottish Breast Unknown; 7.3 FDR: 2 (Lung); SDR: 5 (Breast; Breast; Unknown; Unknown) 42 M Caucasian Breast 72 Y 5.6 FDR: 1 (Skin); SDR: 5 (Skin; Skin; Pancreas; Brain; Brain) 43 F Scottish/Irish Breast 55 Y 10.7 FDR: 2 (Thyroid; Pancreas); SDR: 2 (Breast; Breast; Breast + Ovary) WBC White Blood Cell Count. <i>Hx</i> History. <i>FDR</i> First Degree Relative. <i>SDR</i> Second Degree Relative, <i>XN</i> Yes/No. MA Not available. MA of available.	40	ш	Caucasian	>100 Adenomas	29	z	5.3	FDR: 1 (Breast)
 42 M Caucasian Breast (male) 72 Y 5.6 FDR: 1 (Skin); SDR: 5 (Skin; Pancreas; Brain; Brain) 43 F Scottish/Irish Breast 55 Y 10.7 FDR: 2 (Thyroid; Pancreas); SDR: 2 (Breast; Breast + Ovary) WBC White Blood Cell Count. Ax History. FDR First Degree Relative, V/N Yes/No, MA Not available. 	41	ш	Scottish	Breast	77	Y	7.3	FDR: 2 (Lung; Lung); SDR: 5 (Breast; Breast; Unknown; Unknown; Unknown)
 F Scottish/Irish Breast 55 Y FDR: 2 (Thyroid; Pancreas); SDR: 2 (Breast; Breast + Ovary) WBC White Blood Cell Count. Ax History. FDR First Degree Relative, SDR Second Degree Relative, Y/N Yes/No, NA Not available. 	42	٤	Caucasian	Breast (male)	72	~	5.6	FDR: 1 (Skin); SDR: 5 (Skin; Skin; Pancreas; Brain; Brain)
WBC White Blood Cell Count. Hx History. FDR First Dearee Relative. SDR Second Dearee Relative. Y/N Yes/No. NA Not available.	43	ш	Scottish/Irish	Breast	55	٢	10.7	FDR: 2 (Thyroid; Pancreas); SDR: 2 (Breast; Breast + Ovary)
	WBC Whit	e Blooc	1 Cell Count, Hx History, FDR 1	First Degree Relative, SDR Seco	ond Degree Relative	, Y/N Yes/No, NA Not available.		

3

Americal Constraint Equilable constraint Encodent Inform Description inform Encodent Inform Constraint Encodent Inform Enc	Table 2. derived E	Summar DNA.	y of genetic findings, allele f	fractions, and clini	cal diagnoses in pa	atients with incidenta	I findings identified throu	igh NGS-MGP testing c	on peripheral blood	leukocyte (PBL)-
2 173 CMG-5 pd/mg/31641 55% (6) 23 0% M M M M CH 3 1733 CMG-51 pd/mg/3666 13% (6) 23 0% M 0% M	Patient ID	Gene	PBL Variant		PBL Allele Fraction (Age)	Secondary Finding Category	Direct Skin Biopsy Allele Fraction	Cultured Fibroblast Allele Fraction	Tumour Tissue Allele Fraction	Dx Conclusion
3 733 CVG C5-T DAG 205661 3356 (73) 235 05 05 06 C1 6 793 CAG C5-T DAG 20610 3356 (73) 3356 (73) 3356 (73) 3366 (73) 1356 (74)	2	TP53	c.524 G > A p	.(Arg175His)	5.8% (66) 3.8% (67) 1.3% (68)	2,3	00%	9%0	NA	CH
5 173 CA3C-T pdigraffield 120% (60 23 NM NM NM NM Undy CI (Decended) 7 753 C43C-T pdigraffield 120% (60 23 300 N N N NM	£	TP53	c.747 G > T p	o.(Arg249Ser)	13.9% (78) 6.7% (79)	2,3	0%0	NA	0%	CH
6 733 5486 C 1 D/dry 1967 1338, 50 23 30% M M MM Unloy CH 7 773 733 7.335, 53 33	5	TP53	c.742 C > T p.	۰.(Arg248Trp)	12.0% (69)	2,3	NA	NA	NA	Likely CH (Deceased)
7 173 C.33G.S.A D.Mg348G(b) 1456 (5) NA 21% NA 21% NA 21% NA 73 Total 73	6	TP53	c.586 C > T p.	•.(Arg196*)	13.8% (56)	2,3	3.80%	NA	NA	Likely CH
7 173 C345.A pAngAsticin 23.4% (3) <td></td> <td></td> <td></td> <td></td> <td>14.9% (56)</td> <td></td> <td></td> <td></td> <td></td> <td></td>					14.9% (56)					
8 753 C.11864A Dilys73Ang/s49 32.9% (3) 10 773 C.336.5 A p.(9)43554(-49) 32.9% (7) 2.3 MA MA MA MA Lilely CI (Percented) 11 773 C.635.6 A p.(9)43554(-49) 33.4% (1); 2.3 K17 2.3 K17 C	7	TP53	c.743 G > A p	o.(Arg248Gln)	23.4% (38)	2,3	NA	21%	NA	TP53 mosaic
B Tysis C111 Beldik DL/ys73Aefbr 491 138% (T) 2.3 NM MM MM <thmm< th=""> <thmm< th=""> <thmm< th=""></thmm<></thmm<></thmm<>					21.5% (38) 25.2% (39) 21.2% (40)					
10 193 C33G-A p(dy355e) 32% (T) 23	8	TP53	c.1118delA p.	۰.(Lys373Argfs*49)	13.8% (71)	2,3	NA	NA	NA	Likely CH (Deceased)
11 17-3 556 / T 1000 17-35 C 450 / T 1000	10	TP53	c.733 G > A p	ı.(Gly245Ser)	32.7% (71)	2,3	<i>TP5</i> 3: c.880 G > T, p (Glu294*) 12.2%	All 3 <i>TP53</i> variants 0%	NA	СН
11 173 C659 A G μ(Ty220Cy) 533% (73); (73					32.8% (71)		<i>TP5</i> 3: c.380 C > T, p. (Ser127Phe) 6.2%			
(C1/2-11/-721-7)del whole gene deterion 35% (74), 40% (75) M. (DNA poor quality) 0% 17 783 C45 C-A pArg/37H6) 12/4% (83) 23 20% 0% NA Multiple Myeloma related 17 783 C45 C-A pArg/37H6) 10% (53) 23 20% 0% NA Multiple Myeloma related 14 773 C435 C-A pArg/37H6) 17.8% (82) 23 0% NA NA CH CH 16 7733 C436 G-A pArg/37H6) 17.8% (82) 23 0% (muccle) NA NA CH CH 16 7733 C436 G-A pArg/37H6 10% (63) 2 0% NA NA CH CH 22 A/M C/734, 773/MGC pArg/37H6 10% (63) 2 0% NA NA Likely CH CH 23 A/M C/734, 773/MGC pArg/37H6 10% (63) 2 0% NA NA NA NA Likely CH	11	TP53	c.659 A > G p	o.(Tyr220Cys)	53.3% (74); 82.3% (75)1,3	5.1%	0%	NA	Chronic Lymphocytic Leukemia-related
12 TF33 C BIS G > A p (Ag727Hi) 27.4% (B3) 2.3 2.90% 0% M Multiple Myeloma related 13 TP33 c.347 G > A p (Mg181His) 100% (S7) 2.3 2.00% 0% M M (Mtple Myeloma related 14 TP33 c.337T > A p (Mg181His) 100% (S7) 2.3 N N N N CH 15 TP33 c.816 S > A p (Mg173Fill) 2.00% (S3) 13 N N N N CH 16 TP3 c.816 S T p (Mg177Fill) 2.00% (S3) 13 N N N N CH 18 ATM c.7.21//C1.701 Mole gene defetion 10.4% (7) 2.3 0% N N N CH 20 ATM c.7.21//C1.701 Mole gene defetion 10.5% (S0) 2 0% N N N N N N N N N N N N N			c.(?_21-)_(*21_?)del whole gene	e deletion	35% (74); 40% (75	2)	NA (DNA poor quality)	0%		
13 773 C43C > A p.(Arg181Hs) 106% (37) 2.3 2.20% 0% NA CH 14 753 c337 + A p.(Hs173Gh) 126% (37) 2.3 NA NA CH 15 753 c387 - A p.(Hs173Gh) 126% (37) 2.3 NA NA CH 16 773 c.486 - A p.(Hs173Gh) 200% (37) 1.3 0% (muscle) NA CH 176 773 c.486 - A p.(Hs173Gh) 380% (33) 2 0% (muscle) NA CH 19 ATM c7.21, C12.1044 whole gene deletion 10.5% (62) 2 0% NA CH 19 ATM c7.21, C12.1044 whole gene deletion 10.5% (62) 2 0% NA CH 10 c7.21, C12.1044 whole gene deletion 10.5% (62) 2 0% NA CH 11 c7.21, C12.1044 whole gene deletion 10.5% (62) 2 NA NA NA CH 21	12	TP53	c.818 G > A p.	۰.(Arg273His)	27.4% (83)	2,3	2.90%	0%	NA	Multiple Myeloma related
150% (3) 150% (3) 150% (3) 150% (3) 150% (3) 150% (3) 150% (3) 173 6.837 > A NA NA NA Clickly CH (Deceased) 16 7733 c.438 G > A p.(17) 46') 2.30 0% (muscle) NA NA Clickly CH (Deceased) 16 7733 c.438 G > A p.(17) 46') 200% (3) 1,3 NA NA Clickly CH (Deceased) 18 ATM c.(7.2.1) L'(7.1.1) 46H whole gene delation 10-15% (80) 2 0% (muscle) NA NA CH 22 ATM c.(7.2.1) L'(7.1.1) 46H whole gene delation 10-15% (80) 2 0% NA NA CH 22 ATM c.(7.2.1) L'(7.1.1) 46H whole gene delation 10-15% (80) 1.2 NA NA NA CH 23 ATM c.(7.2.1) L'(7.1.1) 46H whole gene delation 200% (7) 2 0% NA NA Likely CH (Deceased) 24 RCA CR CR NA NA NA NA <t< td=""><td>13</td><td>TP53</td><td>c.542 G > A p.</td><td>.(Arg181His)</td><td>10.6% (52)</td><td>2,3</td><td>2.20%</td><td>0%</td><td>NA</td><td>CH</td></t<>	13	TP53	c.542 G > A p.	.(Arg181His)	10.6% (52)	2,3	2.20%	0%	NA	CH
114 7733 C.377 > A p(His17G(I) 178% (82) 2.3 NA NA NA NA Likely CH (Deceased) 15 7793 c.816 > A p(Mag273His) 10.4% (70) 2.3 0% (muscle) NA NA NA CH 16 7733 c.816 > T p.((ar2714) 2.90% (63) 1.3 NA NA NA NA CH Likely CH 18 A7M c.7(2.1)(72.1)del whole gene deletion 10-15% (80) 2 0% (muscle) NA NA NA CH 19 A7M c.7(2.1)(72.1)del whole gene deletion 10-15% (80) 2 0% NA NA NA CH 22 A7M c.7(2.1)(72.1)del whole gene deletion 10-15% (80) 12 NA NA NA NA CH 23 A7M c.77.2.1/106 (whole gene deletion 20.0% (50) 12 NA NA NA Likely CH Likely CH 24 CHE/2 CHE/2 S0.6% 12					15.0% (53)					
15 7733 C818G > A p./Arg273H(s) 10.4% (70) 2.3 0% (muscle) NA NA CH 16 7733 c.48G > A p.(Trp14o) 290% (63) 1.3 NA NA CH 18 ATM c.(7.21).(721.7)del whole gene deteion 10.3% (80) 2 0% NA NA CH 22 ATM c.(7.21).(721.7)del whole gene deteion 10.15% (80) 2 0% NA NA CH 22 ATM c.(7.21).(721.7)del whole gene deteion 10.3% (80) 2 0% NA NA Ukely CH 22 ATM c.(7.21).(721.3)del whole gene deteion 200% (71) 2 5% NA NA Ukely CH 27 CHEZ c.(111.0.7.1 p.(Hay1337) 50% (63) 2 0.87% NA NA Ukely CH 27 CHEZ c.(111.0.7.1 p.(Hay1337) 50% (63) 2 0.87% NA Lkely CH CHeEX 27 CHEZ c.113	14	TP53	c.537 T > A p.	.(His179Gln)	17.8% (82)	2,3	NA	NA	NA	Likely CH (Deceased)
	15	TP53	c.818 G > A p.	۰.(Arg273His)	10.4% (70)	2,3	0% (muscle)	NA	NA	CH
C811 G > T C811 G > T p.(Gu271') 38.0% (5) 38.0% (5) 2 0% NA CH CH 19 ATM C.(7.2.1)_(*21.7) del whole gene deteion 10-15% (80) 2 5% NA NA NA Likely CH 22 ATM C.(7.2.1)_(*21.7) del whole gene deteion 10-15% (80) 2 5% NA NA NA Likely CH 22 ATM C.(7.2.1)_(*21.7) del whole gene deteion 10-15% (80) 2 5% NA NA Likely CH 24 CHE/Z c.1111C > T p.(Ais371Tyr) 273% (69) 1.2 NA NA Likely CH 27 CHE/Z c.1111C > T p.(Aig335') 50% (59) 2 0.37% NA NA Likely CH 27 CHE/Z c.684-1 G > A 11.7% (68) 2 0.87% NA NA Likely CH 28 RCAI c.195_1196detCA p.(His337) 23.6% (53) 2 0.87% NA NA NA NA <	16	TP53	c. 438 G > A p.	۰.(Trp146*)	29.0% (63)	1,3	NA	NA	NA	Likely CH
18 ATM C(7_21)_(*21_7)del whole gene defetion 10-15% (80) 2 0% NA C(7_21)_(*21_7)del whole gene defetion 10-15% (80) 2 5% NA NA C(7_21)_(*12_7)del whole gene defetion 200% (71) 2 5% NA NA Likely CH 22 ATM c(7_21)_(*21_7)del whole gene defetion 200% (71) 2 5% NA NA Likely CH 24 C(47 cs5035 C T p.(Arg1837'fy) 50% (69) 12 NA NA Likely CH 27 CHER c(1/-21)_(*21_7)del whole gene defetion 20.0% (71) 2 0.87% NA NA Likely CH 27 CHER c(69) 12 NA NA NA Likely CH 28 TG4 NA NA NA NA BRCAI 219 1956delCA p.(14533'f) 7.2% (58) 2 0.87% NA BRCAI 23 BRCAI c.1110 C C T p.(14532) 7.2% (58) 2 NA			c.811G>T p	۰.(Glu271*)	38.0% (63)					
19 ATM C.7736_T737insC p.(Arg25735erfs*7) 15.0% (62) 2 5% NA NA Likely CH 22 ATM c.(721)_1*71_7) del whole gene deletion 200% (71) 2 NA NA Likely CH (Deceased) 24 CHERC c.1111C > T p.(Hai371Ty) 273% (69) 1,2 NA NA Likely CH (Deceased) 27 CHERC c.1111C > T p.(Hai371Ty) 273% (69) 1,2 NA NA Likely CH (Deceased) 27 CHERC c.1111C > T p.(Hai371Ty) 273% (58) 2 0.87% NA NA Likely CH (Deceased) 27 CHERC c.6441 G > A 11.75% (58) 2 0.87% NA NA Likely CH 29 T753 c.375 G > A p.11251 Splice 50% (53) 3 NA NA Likely CH 33 BrCAI c.11951196delCA p.(His427) 7.2% (58) 2 24% NA NA 40 APC c.133_1300del	18	ATM	c.(?_21)_(*21_?)del whole gene	e deletion	10-15% (80)	2	0%	0%	NA	CH
22 ATM c.(721).(*21.2)/del whole gene deletion 200% (71) 2 NA NA NA Likely CH (Deceased) 24 CHEZ c.1111 C > T p.(Hi3371Tyr) 27.3% (69) 1.2 NA NA Likely CH (Deceased) 27 CHEZ c.1111 C > T p.(Arg18357) 50% (69) 2 0.87% NA NA Likely CH 27 CHEX c.1111 C > T p.(Arg18357) 50% (69) 1 NA NA Likely CH 27 CHEX c.684-1 G > A 11.7% (68) 2 0.87% NA NA NA Likely CH 29 TP53 c.375 G > A p.17257 Splice 50% (58) 2 0.87% NA NA Endlemine 33 BRCAI c.1195.1196delCA p.(Hi33397) 23.6% (58) 2 27.0% NA NA Endlemine BRCAI 40 APC c.1333_1390del p.(Hi34627) 7.2% (33) 2 NA NA NA So% (SP) NA So% (SP) NA So% (SP) NA So% (SP) NA	19	ATM	c.7736_7737insC p	۰.(Arg2579Serfs*7)	15.0% (62)	2	5%	NA	NA	Likely CH
24 CHE/2 CI111 C>T p.(His371Tyr) 27.3% (69) 1.2 NA NA Likely Germine BRCA1 27 CHE/2 c.684-1 G>A p.(Arg1835*) 50% (69) 1 NA Likely Germine BRCA1 27 CHE/2 c.684-1 G>A 11.7% (68) 2 0.87% NA Likely Germine BRCA1 29 TP33 c.375 G>A p.1725T Splice 50% (53) 3 NA Full germine BRCA1 33 BRCA1 c.1195_1196deICA p.(Hi3339*) 2.36% (58) 2 0.87% NA Full germine BRCA1 33 BRCA1 c.1195_1196deICA p.(Hi3339*) 2.36% (58) 2 27.0% NA Full germine 40 APC c.1195_1196deICA p.(Hi3462*) 7.2% (33) 2 NA Full germine 41 TP53 c.3136_1 p.(Hi3462*) 1,3 NA NA Full germine 41 TP53 c.195_1196deICA p.(Hi3462*) 7.2% (33) 2 NA NA NA NA 41 TP53 c.1383_1390deI p.(Hi2462*)	22	ATM	c.(?21)_(*21_?)del whole ger	ne deletion	20.0% (71)	2	NA	NA	NA	Likely CH (Deceased)
BRCA1 C.5503 C > T p.(Arg1835*) 50% (69) Likely germine BRCA1 27 CHE/Z c.684-1 (G > A 11.7% (68) 2 0.87% NA Likely germine BRCA1 29 $TP53$ c.375 G > A p.T125T Splice 50% (53) 3 NA Full germine 33 $BRCA1$ c.1195_1196delCA p.T125T Splice 50% (53) 3 NA Full germine 40 APC c.1195_1196delCA p.(His462*) 7.2% (33) 2 NA NA BRCA1 mosaic 40 APC c.1333_1390del p.(His462*) 7.2% (33) 2 NA NA PC PC robit on AF) PC 41 $TP3$ c.743 G > A p.(Arg248Gin) 47.5% (77) 1,3 NA NA PC PC PC c.(?-20)_(*21_2)/del whole gene deletion -30% (77) 1,3 NA NA NA PA PC C.(?-20)_(*21_2)/del whole gene deletion -30% (77) 1,3 NA PA PC C.(?-20)_(*21_2)/del who	24	CHEK2	c.1111C>T p	.(His371Tyr)	27.3% (69)	1,2	NA	NA	NA	Likely CH
27 CHEK2 C.684-1 G>A 11.7% (68) 2 0.87% NA NA Likely CH 29 7753 c. 375 G>A p.7125T Splice 50% (58) 3 NA Full germline 33 BRCA1 c.1195_1196delCA p.(His339*) 2.36% (58) 2 27.0% 24% NA Full germline 40 APC c.1383_1390del p.(His339*) 7.2% (33) 2 NA NA BRCA1 mosaic 41 7753 c.1383_1390del p.(His462*) 7.2% (33) 2 NA NA Present in duodenal APC 41 7753 c.743 G > A p.(His462*) 7.2% (33) 2 NA NA Present in duodenal APC 41 7753 c.743 G > A p.(Aig248Gin) 47.5% (77) 1,3 NA NA 3.5% (breast Likely CH APC c.(?20)_(*21_7)del whole gene deletion ~30% (77) 1,3 3.6% (breast Likely CH APC c.(?20)_(*21_7)del whole gene deletion ~30% (77) 3.3 NA O% O% CH A	;	BRCA1	c.5503C>T p	o.(Arg1835*)	50% (69)			:		Likely germline BRCA1
29 TP53 c. 375 G > A p.T125T Splice TOCK TOCK <thtock< th=""> TOCK TOCK<!--</td--><td>77</td><td>CHEKZ</td><td>c.684-1 u > A</td><td></td><td>11.7% (68) 10.2% (68)</td><td>7</td><td>0.87%</td><td>AN</td><td>NA</td><td>Likely CH</td></thtock<>	77	CHEKZ	c.684-1 u > A		11.7% (68) 10.2% (68)	7	0.87%	AN	NA	Likely CH
33 BRCA1 c.1195_1196delCA p.(His33*) 23.6% (58) 2 27.0% 24% NA BRCA1 mosaic 40 APC c.1383_1390del p.(His33*) 7.2% (58) 2 NA NA BRCA1 mosaic 41 TP53 c.343 (5 A) p.(His462*) 7.2% (33) 2 NA NA present in duodenal APC mosaic 41 TP53 c.743 (5 A) p.(Aig248Gln) 47.5% (77) 1,3 NA NA 3.5% (breast Likely CH 41 TP53 c.743 (5 A) p.(Aig248Gln) 47.5% (77) 1,3 NA NA 3.5% (breast Likely CH 47 TP53 c.72 - 20)_(*21_3) 3.26% (77) 1,3 NA 0% NA 1 47 TP53 c.637 (5 T p.(Aig213*) 32.6% (77) 3 MA 0% 0% CH 42 TP53 c.637 (5 T p.(Aig213*) 37.1% (75) 3 NA 0% 0% CH 43<	29	TP53	c. 375 G > A	T125T Splice	50% (53)	e	NA	50%	NA	Full aermline
40 APC c.1383_1300del p.(His462*) 7.2% (33) 2 NA NA present in duodenal APC mosaic 41 TP53 c.743 G > A p.(Arg248Gln) 47.5% (77) 1,3 NA present in duodenal APC mosaic 41 TP53 c.743 G > A p.(Arg248Gln) 47.5% (77) 1,3 NA NA present in duodenal APC mosaic APC c.(7-20)_(*21_7)del whole gene deletion ~30% (77) 1,3 NA NA 3.5% (breast Likely CH 42 TP53 c.637 C > T p.(Arg213*) 32.6% (73) 3 NA 0% NA Thourn) 43 TP53 c.818 G > A p.(Arg213*) 37.1% (75) 3 NA 0% NA CH	33	BRCA1	c.1195_1196delCA p.	(His339*)	23.6% (58)	5 7	27.0%	24%	NA	BRCA1 mosaic
41 TP53 C.743 G > A p.(Arg248Gln) 47.5% (77) 1,3 NA 3.5% (breast tunnour) Likely CH APC c.(?20)_(*21_7)del whole gene deletion ~30% (77) 3 3 3.5% (breast tunnour) Likely CH 42 TP53 c.637 C > T p.(Arg213*) 32.6% (73) 3 NA 0% NA 43 TP53 c.818 G > A p.(Arg213*) 37.1% (75) 3 NA 0% NA CH	40	APC	c.1383_1390del p insATGAATGA	ı.(His462*)	7.2% (33)	2	NA	NA	present in duodenal polyp (no AF)	APC mosaic
APC c.(?20)_(*21_7)del whole gene deletion ~30% (77) NA NA 42 TP53 c.637 C > T p.(Arg213*) 32.6% (73) 3 NA O% NA CH 43 TP53 c.818 G > A p.(Arg273His) 37.1% (75) 3 NA O% NA CH	41	TP53	c.743 G > A p	.(Arg248Gln)	47.5% (77)	1,3	NA	NA	3.5% (breast tumour)	Likely CH
42 TP53 c.637 C > T p.(Arg213*) 32.6% (73) 3 NA 0% NA CH 43 TP53 c.818 G > A p.(Arg273 His) 37.1% (75) 3 NA 0% NA CH		APC	c.(?20)_(*21_?)del whole ger	ne deletion	~30% (77)				NA	
43 TP53 c.818G>A p.(Arg273His) 37.1% (75) 3 NA 0% NA CH	42	TP53	c.637 C > T p.	۰.(Arg213*)	32.6% (73)	3	NA	0%	NA	CH
	43	TP53	c.818 G > A p.	.(Arg273His)	37.1% (75)	3	NA	0%	NA	CH

N. Maani et al.



Fig. 1 Genetic findings. Recommended diagnostic algorithm for patients presenting with potential incidental findings identified through NGS-MGP testing on peripheral blood leukocyte (PBL)-derived DNA. Genetic findings in individuals undergoing germline NGS-MGP testing on PBLs are classified in one of three categories and subsequently undergo further testing to identify downstream surveillance and diagnosis. This includes secondary tissue analysis (culture skin biopsy preferred) and medical chart review. CBC complete blood count.

families harbouring *TP53* variants). We propose a clinical algorithm to determine the type of incidental finding and management of these cases (Fig. 1).

Aspects of our clinical workflow include secondary tissue analysis (cultured fibroblasts preferred) and a thorough review of CBC and medical records, builds on previously published algorithms⁸. The clinical implications of incidental findings can be significant and delineating their origin may directly impact patient management. Patients harbouring germline and mosaic pathogenic variants need to undergo annual radiological surveillance and/or surgical intervention. This is particularly relevant for *TP53* variants, which is the only gene on the NGS-MGP that is clearly associated with CH and overlaps with the highly penetrant hereditary Li-Fraumeni syndrome.

Based on their constellation of clinical findings, the majority of patients in our cohort were diagnosed as CH (33.3%) or likely CH (41.6%). Although CH is not considered a hematologic disorder, it represents a risk factor and a potential precursor for the evolution of various hematologic malignancies (myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML))⁴⁰, as well as cardiovascular complications^{18,24–28}. Indeed, this emphasizes the importance of identifying and coordinating appropriate follow-up for CH patients, particularly those who have undergone chemotherapy. Of note, one CH patient in our cohort (Patient 6) was young (56 y) and had no history of chemotherapy or known cancer diagnosis at the time of testing (Table 1, Table 2). While rare, CH has been observed in healthy individuals <50 years of age⁴¹, demonstrating the importance of additional investigations for all patients with potential incidental findings, irrespective of age or cancer history.

In emphasizing certain cases, we seek to demonstrate complexities in the work-up of these patients, including some challenges in secondary tissue testing such as the limitations of direct skin punch biopsies and tumour tissue testing. These included, but were not limited to, the presence of somatic variants in the skin (Patient 10) and PBL contamination (Patients 12 and 13). Limitations of tumour testing included tissue infiltration of lymphocytes (Patient 41) and unreliable AFs (Patient 40). Indeed, streamlining secondary tissue testing is often complicated by logistical barriers in diagnostic laboratories. While many laboratories lack the appropriate resources to perform secondary tissue testing, the cases demonstrated here support the analysis of secondary tissues in certain clinical scenarios. This could include buccal swabs as an alternative to skin biopsy to distinguish CH from germline variants⁴².

The interpretation of incidental findings identified through NGS-MGP should be undertaken with high clinical suspicion, thorough genetic counselling and in communication with the molecular genetics laboratory and the patient. An example of this process is emphasized through a review of Patient 41. This case involved a family where genetic analysis of the proband identified an apparently heterozygous TP53 gene mutation at an AF of 47.5%, a finding which was initially reported as a germline variant (Table 2). Upon genetic counsellor review, the family history did not fulfill Chompret's Criteria^{8,39} and it became apparent that this result was not consistent with Li-Fraumeni Syndrome, likely representing an incidental finding. Through subsequent review of NGS-MGP data, an additional deletion in APC was identified at 30% allele fraction, strongly suggesting that the apparently heterozygous TP53 variant was likely not germline. This was confirmed by the absence of the TP53 variant in a secondary tissue (Table 2). Given that Patient 41 had no history of polyposis and was not initially counselled for the analysis of APC, this scenario emphasizes the importance of reviewing the patient's cancer pedigree in context with genetic testing results. Genetic testing data that are secondary to the initial indication for testing may be of significant value in the interpretation of the final result for the patient. With the widespread use of NGS-MGP testing, analogous scenarios will become increasingly prevalent. Genetic counselling should involve a discussion of potential incidental results and thus raise awareness of the clinical implications.

Incidental findings represent a growing and unintended consequence of NGS-MGP testing in cancer patients. There exists a pressing need to properly advise patients of the different risks associated with incidental findings and the impact they may have on future care for themselves and their relatives. This includes patients with an atypical presentation of a germline hereditary cancer syndrome, post-zygotic mosaicism, CH, or hematologic malignancy. True germline and mosaic cases have implications for cancer risk in patients and their family members. In contrast, hematologic malignancies and CH require significantly different medical management strategies and are unlikely to affect family members. Moreover, with limited understanding of the etiology and significance of incidental findings, genetic testing of these variants should be offered to all offspring and other family members to determine transmission of the variant and assess segregation¹³.

Given that the use of NGS-MGP testing for cancer susceptibility genes has increased, the identification of incidental findings will become more pervasive amongst genetics clinics. To address this, we propose the adoption of a clinical workflow that will streamline the management of these patients. It is anticipated that future larger studies will demonstrate the impact of this workflow in wider populations.

METHODS

Patient population

A retrospective chart review of patients who underwent NGS-MGP testing was conducted to identify genetic testing results suggestive of a non-germline incidental finding (mosaic, CH, hematologic malignancy). Patients with a personal and/or strong family history of hereditary cancer who underwent germline NGS-MGP testing at the clinicial diagnostic laboratory at London Health Sciences Centre between January 1, 2016 and December 31, 2019 were reviewed. The inclusion criteria were: Category 1) multiple pathogenic or likely pathogenic variants in the same individual; Category 2) presence of likely pathogenic or pathogenic variants at low AFs (10-30%); and/or Category 3) patients harbouring pathogenic TP53 variants not fulfilling any of the criteria for LFS (i.e. Chompret criteria^{8,39}). Of note, three patient samples (Patients 2, 33, 40) were initially tested at an external laboratory and NGS-MGP was repeated at London Health Sciences Centre. Participants not meeting the inclusion criteria were excluded. Ethical approval was obtained from all sites by the Research Ethics Committees (University Health Network REB: 18-5484; London Health Sciences Centre REB: R-20-354; Sinai Health System REB: 03-0231-U). A waiver of consent was provided by all three Research Ethics Committees

Data collection and analysis

For patients fulfilling an inclusion criteria, secondary tissues and/or blood collected at different time points were obtained when available for NGS-MGP testing. Secondary tissues included skin biopsy (with or without fibroblast culture), other normal tissues (e.g. muscle) and tumour tissue. Secondary tissue analysis was not conducted on patients who did not fulfill the inclusion criteria as their NGS-MGP results were not considered unexpected. A review of medical records was completed, including hematology, pathology and screening reports. Collected information included type of genetic testing, gene variant, date of referral for genetic testing, date of consultation, as well as cancer diagnoses, including modality of detection, pathology and treatment. Descriptive statistics were used to describe clinical findings in the patient population.

Genetic testing

All genetic testing was done in a clinical molecular genetics laboratory (London Health Sciences Centre) and allele fractions were reported on all cases.

DNA extraction

Genomic DNA from blood samples were isolated by standard protocols (MagNA Pure system, Roche Diagnostics, Laval, QC, Canada). DNA was quantified through absorbance with a DTX 880 Multimode Detector (Beckman Coulter, Brea, CA).

Next-generation sequencing analysis

Genes included on the NGS-MPG panel include: APC (incl. 5'UTR), ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, CTNNA1, EPCAM, FANCC, FANCM, FLCN, GREM1, HOXB13, MEN1, MLH1 (incl. 5'UTR), MSH2, MSH3, MSH6, MUTYH, NBN, NTHL1, PALB2, PMS2, POLE, POLD1, PTEN (incl. 5'UTR), RAD51C, RAD51D, SDHB, SMAD4, STK11, TP53. All coding exons and 20 base pairs of flanking non-coding sequences were enriched using a custom targeted hybrid protocol. Libraries were prepared with 100 ng of genomic

DNA fragmented to 180 to 220 bp using a Covaris E220 Series Focusedultrasonicator (Covaris, Inc., Woburn, MA). Each sample library was ligated with a specific barcode index according to the manufacturer's protocol (Roche NimbleGen, Inc., Madison, WI) and assessed for guantification and size distribution using the Qubit fluorometer (Life Technologies) and 2200 TapeStation (Agilent Technologies, Santa Clara, CA) respectively. DNA libraries were pooled as 24-plex and captured using the SegCap EZ Choice Library system (Roche NimbleGen, Inc.). Captured libraries underwent appropriate quality control analysis and were diluted to a concentration of 4nmol/L to process for sequencing according to the manufacturer's instructions (Illumina, San Diego, CA). Library concentration for sequencing was 10pmol/L with a 1% PhiX spike-in. Libraries were sequenced using the MiSeq version 2 reagent kit, generating 2 x 150 bp paired-end reads using the MiSeq fastq generation mode (Illumina). The average coverage of the panel was between 500-1000x. For the direct skin biopsy for patient 10, to further assess the TP53 variants found in the skin, a second NGS chemistry (Thermo-Fisher solid tumour Hotspot NGS panel) and second NGS sequencer (Ion Torrent S5) was used. Sequence alignment, variant calling and viewing were performed by the NextGENe and Geneticist Assistant software (Softgenetics). Variant interpretation and classification followed ACMG guidelines. Allele fractions of 30% were considered the empirical low threshold for heterozygous calling. This was established based on validation conducted on single nucleotide variants from NGS-MGP panels. While less reliable for copy number variants, a similar allele fraction threshold was used for exon-level deletions and MLPA was used to confirm (below). NGS allele fractions of 30%-70% were considered heterozvaous.

Multiplex ligation dependent probe amplification (MLPA) Analysis

For patients with exon-level deletions on NGS (11, 18, 22, 41) MPLA was used to confirm these findings. Genomic DNA (100 ng) was amplified according to the manufacturer's recommendations (SALSA MLPA kit, MRC Holland, Amsterdam, the Netherlands). PCR products were separated by capillary electrophoresis (ABI 3730, Life Technologies, Thermo Fisher Scientific, Waltham, MA). Copy number alterations were analyzed with Coffalyser. Net software version 131211.1524 (MRC Holland).

Sanger sequencing

Sanger sequencing was used for all cases to confirm the SNVs or small indels identified by NGS panel with >5% of allele fractions. Coding regions and flanking intronic regions (-20bp to +10 bp) were PCR-amplified and sequenced (BigDye Terminator v1.1 cycle sequencing kit, Life Technologies). Sequencing products were separated by capillary electrophoresis on an ABI3730 (Life Technologies) and analyzed with Mutation Surveyor v4.0.7 software (SoftGenetics).

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY

The data that support the findings of this study are available on request from the corresponding author. Raw next-generation sequencing data has been deposited in Sequence Read Archive (SRA): SUB9747032, BioProject #PRJNA734018.

Received: 31 December 2020; Accepted: 9 June 2021; Published online: 19 July 2021

REFERENCES

- Meldrum, C., Doyle, M. A. & Tothill, R. W. Next-generation sequencing for cancer diagnostics: a practical perspective. *Clin. Biochem. Rev.* 32, 177–195 (2011).
- Guidugli, L. et al. Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes. *Leukemia* 31, 1226–1229 (2017).
- Coffee, B. et al. Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel. *Cancer Genet.* 211, 5–8 (2017).

- Nagahashi, M. et al. Next generation sequencing-based gene panel tests for the management of solid tumors. *Cancer Sci.* 110, 6–15 (2019).
- Coombs, C. C. et al. Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays. *Clin. Cancer Res.* 24, 5918–5924 (2018).
- DiNardo, C. D. et al. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. *Cancer* **124**, 2704–2713 (2018).
- Robson, M. E. et al. American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J. Clin. Oncol. 33, 3660–3667 (2015).
- Batalini, F. et al. Li-Fraumeni syndrome: not a straightforward diagnosis anymore —the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. *Breast Cancer Res.* 21, 107 (2019).
- Cohen, A. S. A., Wilson, S. L., Trinh, J. & Ye, X. C. Detecting somatic mosaicism: considerations and clinical implications. *Clin. Genet.* 87, 554–562 (2015).
- Freed, D., Stevens, E. L. & Pevsner, J. Somatic mosaicism in the human genome. Genes 5, 1064–1094 (2014).
- Beck, T. F., Mullikin, J. C., NISC Comparative Sequencing Program & Biesecker, L. G. Systematic evaluation of sanger validation of next-generation sequencing variants. *Clin. Chem.* 62, 647–654 (2016).
- Slavin, T. P. et al. Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing. *Cancer Genet.* 235–236, 31–38 (2019).
- Weitzel, J. N. et al. Somatic TP53 variants frequently confound germ-line testing results. *Genet. Med.* 20, 809–816 (2018).
- Mester, J. L. et al. Apparently heterozygous TP53 pathogenic variants may be blood limited in patients undergoing hereditary cancer panel. *Test. J. Mol. Diagn. JMD* 22, 396–404 (2020).
- Renaux-Petel, M. et al. Contribution of de novo and mosaic *TP53* mutations to Li-Fraumeni syndrome. J. Med. Genet. 55, 173–180 (2018).
- Tan, N. et al. Is 'incidental finding' the best term?: a study of patients' preferences. Genet. Med. 19, 176–181 (2017).
- Cushman-Vokoun, A. et al. Laboratory and clinical implications of incidental and secondary germline findings during tumor testing. *Arch. Pathol. Lab. Med.* https:// doi.org/10.5858/arpa.2020-0025-CP.
- Dorsheimer, L. et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. *JAMA Cardiol.* 4, 25 (2019).
- 19. Steensma, D. P. Clinical implications of clonal hematopoiesis. *Mayo Clin. Proc.* 93, 1122–1130 (2018).
- Coombs, C. C. et al. Therapy-related clonal hematopoiesis in patients with nonhematologic cancers is common and associated with adverse clinical outcomes. *Cell Stem Cell* **21**, 374–382.e4 (2017).
- 21. Boettcher, S. & Ebert, B. L. Clonal hematopoiesis of indeterminate potential. J. Clin. Oncol. 5.
- 22. Ptashkin, R. N. et al. Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors. *JAMA Oncol.* **4**, 1589 (2018).
- 23. Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. *Nat. Med.* **20**, 1472–1478 (2014).
- Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111–121 (2017).
- Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
- Gillis, N. K. et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. *Lancet Oncol.* 18, 112–121 (2017).
- Libby, P. & Ebert, B. L. CHIP (Clonal Hematopoiesis of Indeterminate Potential): potent and newly recognized contributor to cardiovascular risk. *Circulation* 138, 666–668 (2018).
- Calvillo-Argüelles, O. et al. Connections between clonal hematopoiesis, cardiovascular disease, and cancer: a review. JAMA Cardiol. 4, 380 (2019).
- Bolton, K. L. et al. Managing clonal hematopoiesis in patients with solid tumors. J. Clin. Oncol. 37, 7–11 (2019).
- Campbell, I. M., Shaw, C. A., Stankiewicz, P. & Lupski, J. R. Somatic mosaicism: implications for disease and transmission genetics. *Trends Genet. TIG* 31, 382–392 (2015).
- Forsberg, L. A., Gisselsson, D. & Dumanski, J. P. Mosaicism in health and disease — clones picking up speed. *Nat. Rev. Genet.* 18, 128–142 (2017).
- Konnick, E. Q. & Pritchard, C. C. Germline, hematopoietic, mosaic, and somatic variation: interplay between inherited and acquired genetic alterations in disease assessment. *Genome Med.* 8, (2016).

- Steensma, D. P. Clinical consequences of clonal hematopoiesis of indeterminate potential. *Blood Adv.* 2, 3404–3410 (2018).
- Acuna-Hidalgo, R. et al. Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life. *Am. J. Hum. Genet.* **101**, 50–64 (2017).
- McNulty, S. N. et al. Diagnostic utility of next-generation sequencing for disorders of somatic mosaicism: a five-year cumulative cohort. Am. J. Hum. Genet. 105, 734–746 (2019).
- Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. - Abstract - Europe PMC. https://europepmc. org/article/MED/25999502.
- 37. Yizhak, K. et al. RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. *Science* **364**, (2019).
- Hernando, B. et al. The effect of age on the acquisition and selection of cancer driver mutations in sun-exposed normal skin. Ann. Oncol. 32, 412–421 (2021).
- Bougeard, G. et al. Revisiting Li-fraumeni syndrome from TP53 mutation carriers. J. Clin. Oncol. 33, 2345–2352 (2015).
- 40. Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *N. Engl. J. Med.* **371**, 2477–2487 (2014).
- Guermouche, H. et al. High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers. *Blood Adv.* 4, 3550–3557 (2020).
- Midic, D. et al. Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders. *Leukemia* 34, 2198–2205 (2020).

ACKNOWLEDGEMENTS

The authors declare no funding for this research from any funding agency in the public, commercial or not-for-profit sectors. R.H.K. is supported by the Bhalwani Family Chartiable Foundation.

AUTHOR CONTRIBUTIONS

R.H.K. and H.L. conceptualized the project. R.H.K., N.M., H.L., and K.M.F., planned the manuscript. R.H.K. and N.M. drafted and wrote the manuscript. K.M.F. and H.L. assisted with writing of the manuscript. H.L., P.A., K.P., K.B. and K.S. provided the raw clinical data. K.M.F. and J.M.M. assisted with data curation. R.H.K. and N.M. analyzed and compiled clinical data. N.M., K.P., J.M.M., K.B., K.S., K.M.F., P.A., S.P., S.R.A., H.L., B.S., and R.H.K. reviewed and provided substantial edits to each manuscript draft. R.H.K., N. M., and K.M.F. submitted the manuscript for publication.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41525-021-00224-6.

Correspondence and requests for materials should be addressed to H.L. or R.H.K.

Reprints and permission information is available at http://www.nature.com/ reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021